Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | SQLE | Q14534 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10706181 | 0.98 | KMT2A (0.46) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL118427 | 0.98 | KMT2A (0.46) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL120741 | 0.95 | KMT2A (0.42) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL120742 | 0.95 | KMT2A (0.42) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL121342 | 0.94 | KMT2A (0.41) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL5857342 | 0.94 | KMT2A (0.44) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL5857338 | 0.94 | KMT2A (0.44) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL121994 | 0.94 | KMT2A (0.41) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL123153 | 0.93 | KMT2A (0.43) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL123154 | 0.93 | KMT2A (0.43) | KMT2AALOX15MEN1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215888-A1 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2009-08-27 | — | — | US | claimed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | claimed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2007098591-A2 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2007-09-07 | — | — | WO | claimed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | claimed |
| EP-3324930-B1 | DELIVERY OF DRUG NANOPARTICLES AND METHODS OF USE THEREOF | DFB SORIA LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20240252441-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2024-08-01 | — | — | US | disclosed |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-3595633-B1 | TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANES | DFB SORIA LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | DFB SORIA, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2007098591-A2 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2007-09-07 | — | — | WO | disclosed |
| US-20070183936-A1 | Apparatus and methods for evaluating the barrier properties of a membrane | NUVO RESEARCH US, INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006091297-A2 | MOLECULES TO ENHANCE PERCUTANEOUS DELIVERY AND METHODS FOR DISCOVERY THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1680223-A2 | APPARATUS AND METHODS FOR EVALUATING THE BARRIER PROPERTIES OF A MEMBRANE | Fqubed, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005012549-A2 | APPARATUS AND METHODS FOR EVALUATING THE BARRIER PROPERTIES OF A MEMBRANE | FQUBED, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12329858-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | KMT2A 4814/4885ALOX15 2657/4885MEN1 1285/4885 |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | KMT2A 3780/4885ALOX15 3316/4885MEN1 1571/4885 |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | KRT18, TUBB3, TUBA3E | KMT2A 2936/4885ALOX15 2976/4885MEN1 1701/4885 |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | KMT2A 3780/4885ALOX15 3316/4885MEN1 1571/4885 |
| US-20240252441-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | KMT2A 4814/4885ALOX15 2657/4885MEN1 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.